229 related articles for article (PubMed ID: 34141607)
1. Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor.
Chen Y; Zhang C; Peng Z; Qi C; Gong J; Zhang X; Li J; Shen L
Front Oncol; 2021; 11():589022. PubMed ID: 34141607
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors.
Cao J; Chen Q; Bai X; Liu L; Ma W; Lin C; Lu F; Zhou T; Zhan J; Huang Y; Yang Y; Luo F; Zhao H
Ann Med; 2023; 55(2):2280002. PubMed ID: 38065623
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of lymphocyte-to-monocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Mei P; Feng W; Zhan Y; Guo X
Front Immunol; 2023; 14():1321584. PubMed ID: 38090560
[TBL] [Abstract][Full Text] [Related]
4. The lymphocyte-to-monocyte ratio could predict the efficacy of PD-1 inhibitors in patients with advanced cancer.
Xiao L; Li L; Chen G; Zhang Y; Gao Q
Transl Cancer Res; 2020 Jul; 9(7):4111-4120. PubMed ID: 35117780
[TBL] [Abstract][Full Text] [Related]
5. The Kinetic Changes of Systemic Inflammatory Factors during Bevacizumab Treatment and Its Prognostic Role in Advanced Non-small Cell Lung Cancer Patients.
Li B; Wang S; Li C; Guo M; Xu Y; Sun X; Yu J; Wang L
J Cancer; 2019; 10(21):5082-5089. PubMed ID: 31602260
[No Abstract] [Full Text] [Related]
6. Prognostic values of inflammatory indexes in bevacizumab-treated patients with advanced non-small-cell lung cancer.
Yang J; Deng M; Bi M; Wang Y; Qiao X; Zhang S
Future Sci OA; 2022 Mar; 8(5):FSO798. PubMed ID: 35662746
[TBL] [Abstract][Full Text] [Related]
7. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors.
Wan L; Wu C; Luo S; Xie X
Dis Markers; 2022; 2022():3610038. PubMed ID: 36590752
[TBL] [Abstract][Full Text] [Related]
9. Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer.
Tomás TC; Eiriz I; Vitorino M; Vicente R; Gramaça J; Oliveira AG; Luz P; Baleiras M; Spencer AS; Costa LL; Liu P; Mendonça J; Dinis M; Padrão T; Correia M; Atalaia G; Silva M; Fiúza T
World J Gastrointest Oncol; 2022 Jul; 14(7):1307-1323. PubMed ID: 36051098
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer.
Chen Y; Wang W; Zhang X; Yu X; Xi K; Wen Y; Wang G; Feng X; Zhang L
Cancer Manag Res; 2018; 10():5411-5422. PubMed ID: 30519089
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte-monocyte ratio as a predictive marker for pathological complete response to neoadjuvant therapy in esophageal squamous cell carcinoma.
Zhao K; Wang C; Shi F; Li M; Yu J
Transl Cancer Res; 2020 Jun; 9(6):3842-3853. PubMed ID: 35117751
[TBL] [Abstract][Full Text] [Related]
12. Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab.
Sánchez-Gastaldo A; Muñoz-Fuentes MA; Molina-Pinelo S; Alonso-García M; Boyero L; Bernabé-Caro R
Transl Lung Cancer Res; 2021 Jun; 10(6):2509-2522. PubMed ID: 34295658
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Progression-Free Survival and Overall Survival in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Center Experience.
Barua SK; Singh Y; Baruah SJ; T P R; Bagchi PK; Sarma D; Phukan M
World J Oncol; 2019 Apr; 10(2):101-111. PubMed ID: 31068990
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Peripheral Inflammatory Markers in Preoperative Mucosal Melanoma: A Multicenter Retrospective Study.
Wang Y; Zhang H; Yang Y; Zhang T; Ma X
Front Oncol; 2019; 9():995. PubMed ID: 31649874
[No Abstract] [Full Text] [Related]
15. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI).
Mandaliya H; Jones M; Oldmeadow C; Nordman II
Transl Lung Cancer Res; 2019 Dec; 8(6):886-894. PubMed ID: 32010567
[TBL] [Abstract][Full Text] [Related]
16. Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin.
Fausti V; De Vita A; Vanni S; Ghini V; Gurrieri L; Riva N; Casadei R; Maraldi M; Ercolani G; Cavaliere D; Pacilio CA; Pieri F; Foca F; Bongiovanni A; Ranallo N; Calpona S; Frassineti GL; Ibrahim T; Mercatali L
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831421
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis.
Peng H; Luo X
Cancer Cell Int; 2019; 19():70. PubMed ID: 30962764
[TBL] [Abstract][Full Text] [Related]
18. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors.
Mesti T; Grašič Kuhar C; Ocvirk J
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979727
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization and radiofrequency ablation.
Shen Y; Wang H; Chen X; Li W; Chen J
Onco Targets Ther; 2019; 12():7129-7137. PubMed ID: 31564897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
